Garth Lees-Rolfe
Finanzdirektor/CFO bei INHIBIKASE THERAPEUTICS, INC.
Vermögen: - $ am 31.05.2024
Aktive Positionen von Garth Lees-Rolfe
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| INHIBIKASE THERAPEUTICS, INC. | Finanzdirektor/CFO | 31.03.2024 | - |
| Corporate Officer/Principal | 01.11.2022 | 31.03.2024 |
Karriereverlauf von Garth Lees-Rolfe
Ehemalige bekannte Positionen von Garth Lees-Rolfe
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| F-STAR THERAPEUTICS, INC. | Corporate Officer/Principal | 01.12.2021 | 01.11.2022 |
Ausbildung von Garth Lees-Rolfe
| Queensland University of Technology | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 2 |
| Australien | 2 |
| Vereinigtes Königreich | 2 |
Operativ
| Corporate Officer/Principal | 2 |
| Director of Finance/CFO | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| INHIBIKASE THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
F-star Therapeutics, Inc.
 F-star Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
- Börse
- Insiders
- Garth Lees-Rolfe
- Erfahrung
